Information Provided By: 
Fly News Breaks for April 11, 2016
PBYI
Apr 11, 2016 | 07:37 EDT
UBS analyst Matthew Roden points to several events over the past year that lead him to lower his sales forecast for Puma Biotechnology's neratinib and cut his price target on the stock to $60 from $235. However, he still thinks the stock is "significantly" undervalued, based on either its stand-alone value or based on the strategic value of a wholly-owned cancer asset with blockbuster potential to a possible suitor. The firm keeps a Buy rating on Puma shares.
News For PBYI From the Last 2 Days
There are no results for your query PBYI
